220 related articles for article (PubMed ID: 24762809)
21. Acquired hypermethylation of the P16INK4A promoter in abdominal paraganglioma: relation to adverse tumor phenotype and predisposing mutation.
Kiss NB; Muth A; Andreasson A; Juhlin CC; Geli J; Bäckdahl M; Höög A; Wängberg B; Nilsson O; Ahlman H; Larsson C
Endocr Relat Cancer; 2013 Feb; 20(1):65-78. PubMed ID: 23154831
[TBL] [Abstract][Full Text] [Related]
22. Genetics and epigenetics in small intestinal neuroendocrine tumours.
Stålberg P; Westin G; Thirlwell C
J Intern Med; 2016 Dec; 280(6):584-594. PubMed ID: 27306880
[TBL] [Abstract][Full Text] [Related]
23. PTPRM, a candidate tumor suppressor gene in small intestinal neuroendocrine tumors.
Barazeghi E; Hellman P; Westin G; Stålberg P
Endocr Connect; 2019 Aug; 8(8):1126-1135. PubMed ID: 31349215
[TBL] [Abstract][Full Text] [Related]
24. Differential Protein Expression in Small Intestinal Neuroendocrine Tumors and Liver Metastases.
Kim MK; Ye F; Wang D; Cui M; Ward SC; Warner RR; Roayaie S; Shafir M; Schwartz M; Zhang D; Itzkowitz S
Pancreas; 2016 Apr; 45(4):528-32. PubMed ID: 26474427
[TBL] [Abstract][Full Text] [Related]
25. Quantitative global and gene-specific promoter methylation in relation to biological properties of neuroblastomas.
Kiss NB; Kogner P; Johnsen JI; Martinsson T; Larsson C; Geli J
BMC Med Genet; 2012 Sep; 13():83. PubMed ID: 22984959
[TBL] [Abstract][Full Text] [Related]
26. Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine.
Simbolo M; Vicentini C; Mafficini A; Fassan M; Pedron S; Corbo V; Mastracci L; Rusev B; Pedrazzani C; Landoni L; Grillo F; Cingarlini S; Rindi G; Luchini C; Scarpa A; Lawlor RT
Virchows Arch; 2018 Dec; 473(6):709-717. PubMed ID: 30219970
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic regulation of SST
Klomp MJ; Refardt J; van Koetsveld PM; Campana C; Dalm SU; Dogan F; van Velthuysen MF; Feelders RA; de Herder WW; Hofland J; Hofland LJ
Front Endocrinol (Lausanne); 2023; 14():1184436. PubMed ID: 37223009
[TBL] [Abstract][Full Text] [Related]
28. Promoter methylation status of tumor suppressor genes and inhibition of expression of DNA methyltransferase 1 in non-small cell lung cancer.
Liu B; Song J; Luan J; Sun X; Bai J; Wang H; Li A; Zhang L; Feng X; Du Z
Exp Biol Med (Maywood); 2016 Aug; 241(14):1531-9. PubMed ID: 27190263
[TBL] [Abstract][Full Text] [Related]
29. Proteomics identifies neddylation as a potential therapy target in small intestinal neuroendocrine tumors.
Fotouhi O; Kjellin H; Juhlin CC; Pan Y; Vesterlund M; Ghaderi M; Yousef A; Andersson-Sand H; Kharaziha P; Caramuta S; Kjellman M; Zedenius J; Larsson C; Orre LM
Oncogene; 2019 Oct; 38(43):6881-6897. PubMed ID: 31406256
[TBL] [Abstract][Full Text] [Related]
30. RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells.
Suzuki M; Sunaga N; Shames DS; Toyooka S; Gazdar AF; Minna JD
Cancer Res; 2004 May; 64(9):3137-43. PubMed ID: 15126351
[TBL] [Abstract][Full Text] [Related]
31. Global and gene-specific promoter methylation analysis in primary hyperparathyroidism.
Sulaiman L; Juhlin CC; Nilsson IL; Fotouhi O; Larsson C; Hashemi J
Epigenetics; 2013 Jun; 8(6):646-55. PubMed ID: 23764768
[TBL] [Abstract][Full Text] [Related]
32. Melatonin Immunoreactivity in Malignant Small Intestinal Neuroendocrine Tumours.
Söderquist F; Janson ET; Rasmusson AJ; Ali A; Stridsberg M; Cunningham JL
PLoS One; 2016; 11(10):e0164354. PubMed ID: 27736994
[TBL] [Abstract][Full Text] [Related]
33. [Effects of 5-Aza-2-deoxycytidine on DNA methylation of anti-oncogenes in non-small cell lung cancer cells].
Fang HL; Yu ZC; Zhu HB; Jin YT
Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):658-63. PubMed ID: 23159077
[TBL] [Abstract][Full Text] [Related]
34. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines.
Harada K; Toyooka S; Maitra A; Maruyama R; Toyooka KO; Timmons CF; Tomlinson GE; Mastrangelo D; Hay RJ; Minna JD; Gazdar AF
Oncogene; 2002 Jun; 21(27):4345-9. PubMed ID: 12082624
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis.
Liu L; Broaddus RR; Yao JC; Xie S; White JA; Wu TT; Hamilton SR; Rashid A
Mod Pathol; 2005 Dec; 18(12):1632-40. PubMed ID: 16258509
[TBL] [Abstract][Full Text] [Related]
36. Silencing of tumor suppressor genes RASSF1A, SLIT2, and WIF1 by promoter hypermethylation in hereditary breast cancer.
Alvarez C; Tapia T; Cornejo V; Fernandez W; Muñoz A; Camus M; Alvarez M; Devoto L; Carvallo P
Mol Carcinog; 2013 Jun; 52(6):475-87. PubMed ID: 22315090
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic regulation of Wnt signaling pathway in urological cancer.
Costa VL; Henrique R; Ribeiro FR; Carvalho JR; Oliveira J; Lobo F; Teixeira MR; Jerónimo C
Epigenetics; 2010 May; 5(4):343-51. PubMed ID: 20421722
[TBL] [Abstract][Full Text] [Related]
38. A plausible role for actin gamma smooth muscle 2 (ACTG2) in small intestinal neuroendocrine tumorigenesis.
Edfeldt K; Hellman P; Westin G; Stalberg P
BMC Endocr Disord; 2016 Apr; 16():19. PubMed ID: 27107594
[TBL] [Abstract][Full Text] [Related]
39. Somatic Mutations and Genetic Heterogeneity at the CDKN1B Locus in Small Intestinal Neuroendocrine Tumors.
Crona J; Gustavsson T; Norlén O; Edfeldt K; Åkerström T; Westin G; Hellman P; Björklund P; Stålberg P
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1428-35. PubMed ID: 25586243
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors.
Horiguchi K; Tomizawa Y; Tosaka M; Ishiuchi S; Kurihara H; Mori M; Saito N
Oncogene; 2003 Oct; 22(49):7862-5. PubMed ID: 14586413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
